![[Translate to English:]](/fileadmin/_processed_/5/6/csm_willkommen_d34eda0786.png "[Translate to English:]")
![[Translate to English:]](/fileadmin/_processed_/e/1/csm_ueberuns_c1c8cb27e1.png "[Translate to English:]")
![[Translate to English:]](/fileadmin/_processed_/8/5/csm_ACL_11_GrafikFingerTablet_LB8_c4ce258375.jpg "[Translate to English:]")
![[Translate to English:]](/fileadmin/_processed_/b/8/csm_studien_6aaab3c7bf.jpg "[Translate to English:]")
![[Translate to English:]](/fileadmin/_processed_/6/4/csm_publikaitonen_4abdce50fc.png "[Translate to English:]")
TDM Analytics
The Analytical Chemistry Laboratory (ACL) offers therapeutic drug monitoring (TDM ) for selected active ingredients. For this purpose, several instruments for chromatographic and mass spectrometric methods (LC-MS/MS) in combination with effective extraction methods are available to our specialized staff. With their support specific diagnostics can be performed reliably and quickly. The listing below contains a more detailed description of active ingredients with correspondingly deposited request forms (in German).
In order to provide you with the best possible information from our analyses, we ask that you carefully and conscientiously fill out the request forms. Incompletely filled out request forms can lead to rejection of the sample. Please also observe the drug-specific instructions for taking samples.
If you have any questions, please do not hesitate to contact us!
Your
Dr. rer. nat. Jürgen Burhenne
AMBRISENTAN
Status | 10.06.2013 |
Designation | PAH Therapy Monitoring |
Trade name | Volibris® |
| Substance class | Endothelin receptor antagonist |
Analyte(s) | ambrisentan, 4-hydroxymethyl-ambrisentan |
Sample material | At least 250 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 14 days |
Apixaban
Status | 17.05.2016 |
Designation | DOAC therapy monitoring |
Trade name | Eliquis® |
| Substance class | Direct Factor Xa inhibitor |
Analyte(s) | Apixaban |
Sample material | At least 100 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge Li-Heparin blood after collection and store/transport plasma at - 20°C. |
| Method | LC-MS/MS |
Bosentan
Status | 10.06.2013 |
Designation | PAH Therapy Monitoring |
Trade name | Tracleer® |
| Substance class | Endothelin receptor antagonist |
Analyte(s) | bosentan, hydroxy-bosentan, hydroxy-desmethyl-bosentan, desmethyl-bosentan |
Sample Material | At least 1 mL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 14 days |
Dabigatran
Status | 17.05.2016 |
Designation | DOAC therapy monitoring |
Trade name | Pradaxa® |
| Substance class | Direct thrombin inhibitor |
Analyte(s) | Dabigatran |
| Sample material | At least 100 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge Li-Heparin blood after collection and store/transport plasma at - 20°C. |
| Method | LC-MS/MS |
Edoxaban
Status | 17.05.2016 |
Designation | DOAC therapy monitoring |
Trade name | Lixiana® |
| Substance class | Direct Factor Xa inhibitor |
Analyte(s) | Edoxaban |
Sample material | At least 100 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge Li-Heparin blood after collection and store/transport plasma at - 20°C. |
| Method | LC-MS/MS |
Macitentan
Status | 15.06.2021 |
Designation | PAH Therapy Monitoring |
Trade name | Opsumit® |
| Substance class | Endothelin receptor antagonist |
Analyte(s) | macitentan, despropyl macitentan |
Sample material | At least 250 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 14 days |
Riociguat
Status | 07.04.2022 |
Designation | PAH Therapy Monitoring |
Trade name | Adempas ® |
| Substance class | Soluble guanylate cyclase (sGC) stimulant |
Analyte(s) | Riociguat |
Sample material | At least 100 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge Li-Heparin blood after collection and store/transport plasma at -20°C. |
| Method | LC-MS/MS |
Rivaroxaban
Status | 17.05.2016 |
Designation | DOAC therapy monitoring |
Trade name | Xarelto® |
| Substance class | Direct Factor Xa inhibitor |
Analyte(s) | Rivaroxaban |
Sample material | At least 100 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge Li-Heparin blood after collection and store/transport plasma at - 20°C. |
| Method | LC-MS/MS |
Sildenafil
Status | 10.06.2013 |
Designation | PAH Therapy Monitoring |
Trade name | Revatio® |
| Substance class | Phosphodiesterase-5 inhibitor |
Analyte(s) | sildenafil, N-desmethyl-sildenafil |
Sample material | At least 250 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 14 days |
Tadalafil
Status | 10.06.2013 |
Designation | PAH Therapy Monitoring |
Trade name | Adcirca® |
| Substance class | Phosphodiesterase-5 inhibitor |
Analyte(s) | Tadalafil |
Sample material | At least 600 µL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 14 days |
Voriconazole
Status | 10.06.2013 |
Designation | Antifungal therapy monitoring |
Trade name | VFend® |
| Substance class | Azole antifungal |
Analyte(s) | Voriconazole |
Sample material | At least 1 mL plasma |
| Instructions for collection of the sample material | Document time of collection (ideally valley level); centrifuge EDTA or Li-Heparin blood after collection and store/transport plasma at -20 °C. |
| Method | LC-MS/MS |
| Analysis time | within 72 h |
